Aquestive Therapeutics, Inc.

AQST Healthcare Drug Manufacturers Specialty & Generic

Aquestive Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.5 million, down 22.6% from fiscal 2024.

Revenue
−41.0%
EPS
+6.14%
Free cash flow
+40.8%
Total debt
+69.5%

Quarter to September 2026, against a year earlier

3.64 0.16 −4.21%
Market cap
$460.0M
P/E
0.0×
Fwd P/E
−7.7×
Dividend yield
—
F-score
2/9
Altman Z
−2.19
Beneish M
−1.91
Dividend safety
n/a

Aquestive Therapeutics, Inc. (AQST) P/E ratio

Alert me on P/E ratio

Aquestive Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
33 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
TKNO Alpha Teknova, Inc. compare n/m
AQST Aquestive Therapeutics, Inc. n/m
ACB Aurora Cannabis Inc. compare n/m
EVO Evotec AG compare n/m
TLRY Tilray Brands, Inc. compare n/m
EOLS Evolus, Inc. compare n/m
CGC Canopy Growth Corporation compare n/m
IRWD Ironwood Pharmaceuticals, Inc. compare 4.3×
KMDA Kamada Ltd. compare 18.1×
Drug Manufacturers Specialty & Generic industry median 20.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on AQST